menu
seacher

Guangdong team discovered new treatment for advanced ovarian cancer

2018-08-10 12:32:34 Wen Wei Po

The Cancer Center of Sun Yat-sen University announced yesterday that the team of experts led by Professor Huang Xin of the center discovered through two years of clinical research that oral drug combined with the new targeted drug, apatinib, and the anti-tumor drug, Etoposide, has a significant effect on the treatment of advanced ovarian cancer.

The median progression (ie, no worsening) survival of the patients recorded in the protocol (PFS, which refers to the average time between the onset of the drug in the cancer clinical trial and the tumor in the patient detected expansion or deterioration) reached 8.1 months. The current traditional treatment method has been improved for nearly 5 months. Because oral medication can be performed in the outpatient clinic, there is no need for hospitalization. At the same time, the domestic oral medication is low in price and included in medical insurance. The actual expenditure for one treatment is only about 10% of the traditional method.

This first case in the Mainland has been published in the authoritative medical journal.

The research results were published online in the international medical field's top oncology journal Lancet Oncology (Lancet. Tumor), the first clinical research results led by the mainland gynecologic oncologist.

According to Huang Xin, the standard treatment of advanced ovarian cancer mainly includes ovarian cancer comprehensive staging / tumor cytoreductive surgery, and postoperative platinum-based first-line chemotherapy. Surgery skills and treatment options have been improved over the past 20 years, but the 5-year survival rate for patients is still less than 30%.

Leading treatment creates no need for hospitalization.

"Platinum drugs are the basis for the treatment of advanced ovarian cancer." Huang Xin said that platinum-resistant treatment options are very limited, so it is particularly urgent to find new effective drugs to treat platinum-resistant patients.

Research team member Lan Chunyan introduced that recent clinical research evidence indicates that the combination of anti-angiogenic drugs and chemotherapeutic drugs can effectively improve the prognosis of patients with platinum resistance. However, the latest drug programs of many foreign research teams have problems such as regular intravenous administration and hospitalization, expensive, and hypersensitivity reactions among some patients. At the same time, a variety of anti-angiogenic drugs have not been listed in the Mainland. Therefore, the research team turned their attention to the domestic new generation of small molecule anti-angiogenic targeted drug apatinib.

In August 2016, Professor Huang Xin officially launched a prospective, one-arm, open phase II clinical study of "apatinib combined with etoposide-resistant ovarian epithelial cancer." A total of 35 patients were enrolled in the study and a median progression-free survival of 8.1 months was observed. "The progression-free survival of the median patients in the new program has been extended by nearly 5 months, and other data are also significantly better than the latest international research," said Dr. Wang Wei.

Different from the current methods of clinical use, both apatinib and etoposide are oral preparations, which do not require hospitalization and save a lot of medical resources.

Research team member Professor Huang Huiqiang revealed that the domestic drug apatinib only needs 1,360 yuan (RMB, the same below), the unit price is only 100 yuan, and the cost of a treatment is only 8,000 yuan, both of which have been included in the medical insurance reimbursement, patients just need to pay 20% by themselves. The traditional imported drugs are not included in the medical insurance, and a course of treatment actually pays more than 20,000 yuan.

Currently, the team is in the process of Phase III clinical trials, trying to apply the new method to treat ovarian cancer at different stages of development.

Advertising

COMMENTS

Are you a member?Have you logged in?